Get the Stockscreener App
8.755
3.17%
0.255
Fulcrum Therapeutics Inc stock is traded at $8.755, with a volume of 306.82K.
It is up +3.17% in the last 24 hours and up +34.50% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$8.50
Open:
$8.56
24h Volume:
306.82K
Relative Volume:
0.47
Market Cap:
$473.30M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-5.5411
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
+18.67%
1M Performance:
+34.50%
6M Performance:
+190.38%
1Y Performance:
+119.24%
1-Day Range:
$8.43
$8.915
1-Week Range:
$7.21
$8.915
52-Week Range:
$2.315
$8.915
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
8.75 | 459.78M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.67 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.54 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.68 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
716.03 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
325.75 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
How supply chain issues affect Fulcrum Therapeutics Inc. stockWeekly Earnings Recap & Low Drawdown Trading Techniques - newser.com
Can Fulcrum Therapeutics Inc. stock sustain market leadership2025 Bull vs Bear & High Return Trade Opportunity Guides - newser.com
Pociredir Trial And DBA IND Filing Put Fulcrum Therapeutics On Watchlist - RTTNews
Is Fulcrum Therapeutics Inc. stock trading near support levelsQuarterly Earnings Report & Reliable Price Breakout Signals - newser.com
Will Fulcrum Therapeutics Inc. stock outperform value stocksJuly 2025 Outlook & Capital Efficiency Focused Strategies - The British Mountaineering Council
Pattern recognition hints at Fulcrum Therapeutics Inc. upsidePrice Action & Risk Managed Investment Signals - newser.com
What earnings revisions data tells us about Fulcrum Therapeutics Inc.2025 Price Action Summary & Long-Term Growth Plans - newser.com
Strs Ohio Makes New Investment in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Fulcrum Therapeutics Inc. recovery potential after sell offIPO Watch & Entry Point Strategy Guides - newser.com
What does recent volatility data suggest for Fulcrum Therapeutics Inc.Wall Street Watch & Risk Adjusted Buy/Sell Alerts - newser.com
Volume spikes in Fulcrum Therapeutics Inc. stock – what they meanJuly 2025 Outlook & Short-Term High Return Ideas - newser.com
Goldman Sachs Group Inc. Reduces Holdings in Fulcrum Therapeutics, Inc. $FULC - Defense World
Goldman Sachs Group Inc. Sells 139,658 Shares of Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Fulcrum Therapeutics, Inc. $FULC Shares Acquired by Acadian Asset Management LLC - MarketBeat
Whats next for Fulcrum Therapeutics Inc stockJuly 2025 Macro Moves & Real-Time Chart Pattern Alerts - خودرو بانک
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tech Rally: Is FSHP stock forming a triangle patternTrade Performance Summary & Weekly Hot Stock Watchlists - khodrobank.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Down 36.1% in August - MarketBeat
Can Fulcrum Therapeutics Inc deliver alpha2025 Price Momentum & Daily Chart Pattern Signal Reports - خودرو بانک
Price Action: Can Strats Trust Wal Mart Stores Inc. Preferred Security sustain its profitabilityAnalyst Upgrade & Daily Oversold Bounce Ideas - khodrobank.com
Technical analysis overview for Fulcrum Therapeutics Inc. stockJuly 2025 Analyst Calls & Precise Buy Zone Tips - newser.com
Smart Money: Is Fulcrum Therapeutics Inc stock undervalued right nowJuly 2025 Highlights & Short-Term Swing Trade Alerts - خودرو بانک
Market Outlook: Whats the fair value of Fulcrum Therapeutics Inc stockNew Guidance & Technical Pattern Based Buy Signals - خودرو بانک
EPS Watch: Is Fulcrum Therapeutics Inc forming higher highs and higher lowsTrade Analysis Report & Accurate Buy Signal Notifications - khodrobank.com
Published on: 2025-09-19 12:52:11 - khodrobank.com
CEO Moves: Is Fulcrum Therapeutics Inc. forming higher highs and higher lows2025 EndofYear Setup & Real-Time Volume Analysis Alerts - khodrobank.com
Fulcrum Therapeutics jumps amid takeover speculation - MSN
H.C. Wainwright Maintains Fulcrum Therapeutics(FULC.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Acadian Asset Management LLC Increases Stock Position in Fulcrum Therapeutics, Inc. $FULC - Defense World
Jacobs Levy Equity Management Inc. Purchases New Holdings in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Here's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation - Yahoo Finance
Aug PostEarnings: Will Fulcrum Therapeutics Inc outperform tech stocksTrade Analysis Summary & Community Verified Trade Signals - خودرو بانک
Risk Check: Can Fulcrum Therapeutics Inc disrupt its industry2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - خودرو بانک
Fulcrum reduces its workforce - MSN
Published on: 2025-09-16 21:20:39 - خودرو بانک
Trading Action: Will Immunocore Holdings plc Depositary Receipt outperform tech stocksTrade Analysis Summary & Free Expert Verified Stock Movement Alerts - خودرو بانک
Guidance Update: Can Fulcrum Therapeutics Inc keep up with sector leadersJuly 2025 Review & Safe Swing Trade Setup Alerts - خودرو بانک
Published on: 2025-09-16 05:16:04 - خودرو بانک
Market Overview: Is IF Bancorp Inc in a long term uptrendStock Surge & High Yield Equity Trading Tips - خودرو بانک
Aug Update: Is Fulcrum Therapeutics Inc in a bullish channelWeekly Investment Recap & Free Technical Confirmation Trade Alerts - khodrobank.com
Market Catalysts: Is Fulcrum Therapeutics Inc benefiting from innovation trendsJuly 2025 Patterns & Expert Approved Momentum Ideas - خودرو بانک
Applying chart zones and confluence areas to Fulcrum Therapeutics Inc.Portfolio Update Summary & Stepwise Entry and Exit Trade Signals - newser.com
BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $6 - 富途牛牛
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Exome Asset Management LLC - MarketBeat
Published on: 2025-09-15 03:06:05 - newser.com
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.15%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):